# NutriBand Inc.: financial statements, quarterly NTRB · Nasdaq · CIK 1676047 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 31 Pages: [Overview](/companies/ntrb.md) · [Financials](/companies/ntrb/financials.md) · [Filings](/companies/ntrb/filings.md) · [Insiders](/companies/ntrb/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ntrb/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [428](/filings/0001213900-24-105201.md) | [525 d](/filings/0001213900-25-036201.md) | [409](/filings/0001213900-25-049455.md) | [443](/filings/0001213900-25-086270.md) | [646](/filings/0001213900-25-120204.md) | [642 d](/filings/0001213900-26-049399.md) | [667](/filings/0001213900-26-067840.md) | [622](/filings/0001213900-26-097701.md) | [346](/filings/0001213900-25-120204.md) | [401 d](/filings/0001213900-26-049399.md) | [433](/filings/0001213900-26-067840.md) | [438](/filings/0001213900-26-097701.md) | | Cost of revenue | $k | [269](/filings/0001213900-24-105201.md) | [343 d](/filings/0001213900-25-036201.md) | [244](/filings/0001213900-25-049455.md) | [341](/filings/0001213900-25-086270.md) | [455](/filings/0001213900-25-120204.md) | [356 d](/filings/0001213900-26-049399.md) | [415](/filings/0001213900-26-067840.md) | [466](/filings/0001213900-26-097701.md) | [278](/filings/0001213900-25-120204.md) | [312 d](/filings/0001213900-26-049399.md) | [237](/filings/0001213900-26-067840.md) | [256](/filings/0001213900-26-097701.md) | | Gross profit | $k | [160](/filings/0001213900-24-105201.md) | [181 d](/filings/0001213900-25-036201.md) | [165](/filings/0001213900-25-049455.md) | [102](/filings/0001213900-25-086270.md) | [191](/filings/0001213900-25-120204.md) | [286 d](/filings/0001213900-26-049399.md) | [252](/filings/0001213900-25-049455.md) | [157](/filings/0001213900-25-086270.md) | [68.5](/filings/0001213900-25-120204.md) | [88.9 d](/filings/0001213900-26-049399.md) | not reported | not reported | | Research and development | $k | [552](/filings/0001213900-24-105201.md) | [563 d](/filings/0001213900-25-036201.md) | [975](/filings/0001213900-25-049455.md) | [774](/filings/0001213900-25-086270.md) | [881](/filings/0001213900-25-120204.md) | [490 d](/filings/0001213900-26-049399.md) | [683](/filings/0001213900-26-067840.md) | [563](/filings/0001213900-26-097701.md) | [457](/filings/0001213900-25-120204.md) | [188 d](/filings/0001213900-26-049399.md) | [247](/filings/0001213900-26-067840.md) | [322](/filings/0001213900-26-097701.md) | | Selling, general and administrative | $k | [1,331](/filings/0001213900-24-105201.md) | [924 d](/filings/0001213900-25-036201.md) | [1,080](/filings/0001213900-25-049455.md) | [737](/filings/0001213900-25-086270.md) | [737](/filings/0001213900-25-120204.md) | [1,760 d](/filings/0001213900-26-049399.md) | [982](/filings/0001213900-26-067840.md) | [1,598](/filings/0001213900-26-097701.md) | [3,492](/filings/0001213900-25-120204.md) | [922 d](/filings/0001213900-26-049399.md) | [1,204](/filings/0001213900-26-067840.md) | [750](/filings/0001213900-26-097701.md) | | Operating income | $k | [(1,724)](/filings/0001213900-24-105201.md) | [(1,306) d](/filings/0001213900-25-036201.md) | [(1,889)](/filings/0001213900-25-049455.md) | [(1,410)](/filings/0001213900-25-086270.md) | [(1,427)](/filings/0001213900-25-120204.md) | [(5,559) d](/filings/0001213900-26-049399.md) | [(1,413)](/filings/0001213900-26-067840.md) | [(2,003)](/filings/0001213900-26-097701.md) | [(3,880)](/filings/0001213900-25-120204.md) | [(1,021) d](/filings/0001213900-26-049399.md) | [(1,254)](/filings/0001213900-26-067840.md) | [(891)](/filings/0001213900-26-097701.md) | | Interest expense | $k | [40.2](/filings/0001213900-23-095208.md) | [23.2 d](/filings/0001213900-24-037996.md) | [2.6](/filings/0001213900-25-049455.md) | [5.0](/filings/0001213900-25-086270.md) | [4.0](/filings/0001213900-25-120204.md) | [3.7 d](/filings/0001213900-26-049399.md) | [2.5](/filings/0001213900-25-049455.md) | [5.8](/filings/0001213900-26-097701.md) | [5.5](/filings/0001213900-25-120204.md) | [5.3 d](/filings/0001213900-26-049399.md) | [5.0](/filings/0001213900-26-067840.md) | [4.9](/filings/0001213900-26-097701.md) | | Net income | $k | [(1,760)](/filings/0001213900-24-105201.md) | [(1,881) d](/filings/0001213900-25-036201.md) | [(1,898)](/filings/0001213900-25-049455.md) | [(1,705)](/filings/0001213900-25-086270.md) | [(1,363)](/filings/0001213900-25-120204.md) | [(5,516) d](/filings/0001213900-26-049399.md) | [(1,389)](/filings/0001213900-26-067840.md) | [(2,000)](/filings/0001213900-26-097701.md) | [(3,872)](/filings/0001213900-25-120204.md) | [(968) d](/filings/0001213900-26-049399.md) | [(1,242)](/filings/0001213900-26-067840.md) | [(881)](/filings/0001213900-26-097701.md) | | Diluted EPS | $ per share | [(0.22)](/filings/0001213900-24-105201.md) | not reported | [(0.21)](/filings/0001213900-25-049455.md) | [(0.15)](/filings/0001213900-25-086270.md) | [(0.12)](/filings/0001213900-25-120204.md) | not reported | [(0.12)](/filings/0001213900-26-067840.md) | [(2.12)](/filings/0001213900-26-097701.md) | [(0.32)](/filings/0001213900-25-120204.md) | not reported | [(0.10)](/filings/0001213900-26-067840.md) | [(0.07)](/filings/0001213900-26-097701.md) | | Basic EPS | $ per share | [(0.22)](/filings/0001213900-24-105201.md) | not reported | [(0.21)](/filings/0001213900-25-049455.md) | [(0.15)](/filings/0001213900-25-086270.md) | [(0.12)](/filings/0001213900-25-120204.md) | not reported | [(0.12)](/filings/0001213900-26-067840.md) | [(2.12)](/filings/0001213900-26-097701.md) | [(0.32)](/filings/0001213900-25-120204.md) | not reported | [(0.10)](/filings/0001213900-26-067840.md) | [(0.07)](/filings/0001213900-26-097701.md) | - Revenue: us-gaap:Revenues - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [1.3](/filings/0001213900-23-095208.md) | [0.5](/filings/0001213900-25-036201.md) | [8.3](/filings/0001213900-24-048363.md) | [6.8](/filings/0001213900-24-075159.md) | [5.7](/filings/0001213900-24-105201.md) | [4.3](/filings/0001213900-26-049399.md) | [3.0](/filings/0001213900-25-049455.md) | [7.0](/filings/0001213900-25-086270.md) | [5.3](/filings/0001213900-25-120204.md) | [4.6](/filings/0001213900-26-097701.md) | [4.0](/filings/0001213900-26-067840.md) | [3.4](/filings/0001213900-26-097701.md) | | Current assets | $m | [2.0](/filings/0001213900-23-095208.md) | [1.0](/filings/0001213900-25-036201.md) | [8.7](/filings/0001213900-24-048363.md) | [7.2](/filings/0001213900-24-075159.md) | [6.2](/filings/0001213900-24-105201.md) | [4.8](/filings/0001213900-26-049399.md) | [3.4](/filings/0001213900-25-049455.md) | [7.5](/filings/0001213900-25-086270.md) | [5.8](/filings/0001213900-25-120204.md) | [5.0](/filings/0001213900-26-097701.md) | [4.4](/filings/0001213900-26-067840.md) | [3.8](/filings/0001213900-26-097701.md) | | Total assets | $m | [8.5](/filings/0001213900-23-095208.md) | [7.5](/filings/0001213900-25-036201.md) | [15.2](/filings/0001213900-24-048363.md) | [13.6](/filings/0001213900-24-075159.md) | [12.5](/filings/0001213900-24-105201.md) | [7.5](/filings/0001213900-26-049399.md) | [6.2](/filings/0001213900-25-049455.md) | [10.2](/filings/0001213900-25-086270.md) | [8.4](/filings/0001213900-25-120204.md) | [7.5](/filings/0001213900-26-097701.md) | [6.9](/filings/0001213900-26-067840.md) | [6.3](/filings/0001213900-26-097701.md) | | Current liabilities | $m | [0.7](/filings/0001213900-23-095208.md) | [1.0](/filings/0001213900-25-036201.md) | [1.4](/filings/0001213900-24-048363.md) | [1.1](/filings/0001213900-24-075159.md) | [1.2](/filings/0001213900-24-105201.md) | [1.0](/filings/0001213900-26-049399.md) | [0.9](/filings/0001213900-25-049455.md) | [1.6](/filings/0001213900-25-086270.md) | [0.8](/filings/0001213900-25-120204.md) | [0.8](/filings/0001213900-26-097701.md) | [0.8](/filings/0001213900-26-067840.md) | [0.9](/filings/0001213900-26-097701.md) | | Total liabilities | $m | [2.8](/filings/0001213900-23-095208.md) | [1.1](/filings/0001213900-25-036201.md) | [1.8](/filings/0001213900-24-048363.md) | [1.2](/filings/0001213900-24-075159.md) | [1.3](/filings/0001213900-24-105201.md) | [1.0](/filings/0001213900-26-049399.md) | [1.0](/filings/0001213900-25-049455.md) | [1.7](/filings/0001213900-25-086270.md) | [0.9](/filings/0001213900-25-120204.md) | [0.9](/filings/0001213900-26-097701.md) | [0.9](/filings/0001213900-26-067840.md) | [1.0](/filings/0001213900-26-097701.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current portion of debt | $m | not reported | [2.0](/filings/0001213900-24-037996.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [5.7](/filings/0001213900-24-105201.md) | [6.4](/filings/0001213900-26-049399.md) | [13.4](/filings/0001213900-25-086270.md) | [12.5](/filings/0001213900-25-120204.md) | [11.2](/filings/0001213900-25-120204.md) | [6.4](/filings/0001213900-26-097701.md) | [5.1](/filings/0001213900-26-097701.md) | [8.5](/filings/0001213900-26-097701.md) | [7.5](/filings/0001213900-25-120204.md) | [6.7](/filings/0001213900-26-097701.md) | [6.0](/filings/0001213900-26-097701.md) | [5.3](/filings/0001213900-26-097701.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: not reported - Current portion of debt: us-gaap:DebtCurrent - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $k | [(1,064) d](/filings/0001213900-24-105201.md) | [(718) d](/filings/0001213900-25-036201.md) | [(834)](/filings/0001213900-25-049455.md) | [(1,544) d](/filings/0001213900-25-086270.md) | [(1,010) d](/filings/0001213900-25-120204.md) | [(1,239) d](/filings/0001213900-26-049399.md) | [(1,337)](/filings/0001213900-26-067840.md) | [(1,313) d](/filings/0001213900-26-097701.md) | [(1,752) d](/filings/0001213900-25-120204.md) | [(732) d](/filings/0001213900-26-049399.md) | [(563)](/filings/0001213900-26-067840.md) | [(585) d](/filings/0001213900-26-097701.md) | | Capital expenditure | $k | [0.0 d](/filings/0001213900-24-105201.md) | [49.1 d](/filings/0001213900-25-036201.md) | [6.2](/filings/0001213900-25-049455.md) | [38.9 d](/filings/0001213900-25-086270.md) | [47.0 d](/filings/0001213900-25-120204.md) | [0.0 d](/filings/0001213900-26-049399.md) | [5.3](/filings/0001213900-26-067840.md) | [0.0 d](/filings/0001213900-26-097701.md) | [0.0 d](/filings/0001213900-25-120204.md) | [0.0 d](/filings/0001213900-26-049399.md) | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [7.8](/filings/0001213900-23-095208.md) | [7.8](/filings/0001213900-24-048363.md) | [7.8](/filings/0001213900-24-075159.md) | [7.8](/filings/0001213900-24-105201.md) | [9.2](/filings/0001213900-25-049455.md) | [11.1](/filings/0001213900-25-086270.md) | [11.1](/filings/0001213900-25-120204.md) | [11.1](/filings/0001213900-26-067840.md) | [11.2](/filings/0001213900-26-097701.md) | [12.1](/filings/0001213900-25-120204.md) | [12.2](/filings/0001213900-26-067840.md) | [12.2](/filings/0001213900-26-097701.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 12,155,683 at 2026-09-04, from the cover of the [10-Q filed 2026-09-04](/filings/0001213900-26-097701.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.